$ADMA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.19 up 72.73% YoY • Reported revenue of $114.49M down -0.27% YoY • ADMA Biologics expects FY 2026 total revenue of $530M to $560M, Adjusted Net Income of $170M to $200M, and Adjusted EBITDA of $265M to $300M. The company withdrew long-term guidance.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.